Company Overview and News

2
Monthly Paid Dividends From All-Cap U.S. Equities And Funds For April

2018-04-06 seekingalpha
April forecast U.S. Exchange monthly-paid dividends, upsides, and net gains: 1. Stocks by yield (99); 2. Stocks by price upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds & Notes (CEICs/ETFs/ETNs) by yield.
Upvote Downvote

 
Building The Perfect Beast: The Brown Bag Portfolio April Update

2018-04-02 seekingalpha
The other day I was asked by one of my readers: "Do you know how much new money you will have to contribute to the BBP each year (month) to reach your dividend goal?" My immediate thought was "Yes, of course - if I can maintain a yield of 6.6% I will need approximately $250,000." Therefore if I have approximately $20,000 invested now and with an approximate 15 year horizon, that leaves me investing $15,333 a year over the next 15 years, or $1277.
Upvote Downvote

1
3 High-Yield Stocks to Avoid

2018-03-29 investorplace
By now, if you have been in the market for a while, you know that a very high yield stock should be looked upon with suspicion. That’s not to say that the yield isn’t for real and sustainable, but a very high-yield stock — something significantly in excess of 9% — may indicate that something is very wrong with the company.
Upvote Downvote

 
Weekly CEF Roundup: Cuts, Cuts And Boosts

2018-03-16 seekingalpha
The Weekly CEF Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund [CEF] sectors in the last week, as well as to highlight recently concluded or upcoming corporate actions on CEFs, such as tender offers. Most of the information has been sourced from CEFInsight (email alerts), Closed-End Fund Center or Morningstar. I will also link to some articles from Seeking Alpha that I have found for useful reading over the past week.
Upvote Downvote

 
OXLC / Oxford Lane Capital Corp. null

2018-03-14 sec.gov
[Letterhead of Eversheds Sutherland (US) LLP] June 19, 2017
Upvote Downvote

 
OXLC / Oxford Lane Capital Corp. null

2018-03-14 sec.gov
[Letterhead of Eversheds Sutherland (US) LLP] August 23, 2017
Upvote Downvote

 
OXLC / Oxford Lane Capital Corp. null

2018-03-14 sec.gov
OXFORD LANE CAPITAL CORP. 8 Sound Shore Drive, Suite 255 Greenwich, CT 06830 (203) 983-5275
Upvote Downvote

1
Your Monthly Paid Dividends From All Cap U.S. Equities And Funds For March

2018-03-08 seekingalpha
March U.S. Exchange monthly-paid dividends, upsides, and net-gains: 1. Stocks by yield (87); 2. Stocks by price-upside (30); 3. Closed-End Investment Companies, Exchange-Traded Funds & Notes (CEICs/ETFs/ETNs) by yield (80).
Upvote Downvote

 
Weekly CEF Roundup: Rebound Week And Karpus Targets MSP

2018-03-02 seekingalpha
23 out of 32 sectors were positive by price this week, and 23 of out 32 sectors were positive by NAV.
Upvote Downvote

 
Eagle Point Credit: Lots Of Cash, Not All Of It 'Income'

2018-02-24 seekingalpha
CLO accounting so complex it is hard to differentiate "cash flow" from "GAAP income" and "Net Investment Income."
Upvote Downvote

 
OXLC / Oxford Lane Capital Corp. 497

2018-02-12 sec.gov
  Filed pursuant to Rule 497 File No. 333-205405   PROSPECTUS SUPPLEMENT   (To Prospectus dated August 24, 2017 February 12, 2018 and Prospectus Supplements dated August 30, 2017 and   November 9, 2017)           Oxford Lane Capital Corp. $200,000,000 Common Stock     This prospectus supplement supplements the prospectus supplement dated November 9, 2017 (the “Second Prospectus Supplement”), the prospectus supplement dated August 30, 2017 (the “First Prospectus Supplement”) and the accompanying
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...